Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
48 hedge funds and large institutions have $47.9M invested in Syros Pharmaceuticals, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
43% more capital invested
Capital invested by funds: $33.5M → $47.9M (+$14.5M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 53 → 48 (-5)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$3.1M |
| 2 |
CA
CHI Advisors
New York
|
+$1.99M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$438K |
| 4 |
BlackRock
New York
|
+$130K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$116K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$86K |
| 2 |
Two Sigma Investments
New York
|
-$61.7K |
| 3 |
Millennium Management
New York
|
-$40.4K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$38.4K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$37.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
Dimensional Fund Advisors
Austin,
Texas
| – | -$37.8K | -12,015 | Closed |
|
|
CWM
52
CarsonAllaria Wealth Management
Glen Carbon,
Illinois
| – | -$328 | -104 | Closed |
|
|
S
53
SignatureFD
Atlanta,
Georgia
| – | -$274 | -87 | Closed |
|
54
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$26 | -7 | -28% |
|
SYRS Hedge Fund Activity: Q3 2023 in Review
48 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q3 2023, worth a combined $47.9M — up 43% from $33.5M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SYRS and 3 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 13 added.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $3.1M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $86K sold.
- 48 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q3 2023, down from 53 in Q2 2023.
- Funds reported $47.9M of Syros Pharmaceuticals, Inc. Common Stock stock for Q3 2023, up 43% quarter-over-quarter.
- 3 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q3 2023 and 6 closed out, a net change of -3 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q3 2023 was Deep Track Capital, an estimated $3.1M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q3 2023 was GSA Capital Partners, an estimated $86K sold.
Based on aggregated 13F filings for Q3 2023.